John W. Ostrominski, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart Failure | 23 | 2024 | 11593 | 3.130 |
Why?
|
Stroke Volume | 16 | 2024 | 5460 | 2.030 |
Why?
|
Glucagon-Like Peptides | 2 | 2024 | 153 | 1.060 |
Why?
|
Incretins | 1 | 2024 | 98 | 0.880 |
Why?
|
Pericarditis | 1 | 2024 | 133 | 0.840 |
Why?
|
Glomerular Filtration Rate | 5 | 2024 | 2154 | 0.830 |
Why?
|
Thrombotic Microangiopathies | 1 | 2023 | 123 | 0.760 |
Why?
|
Diabetes Mellitus, Type 2 | 6 | 2024 | 12075 | 0.760 |
Why?
|
Ventricular Function, Left | 7 | 2024 | 3858 | 0.720 |
Why?
|
Diabetes Mellitus | 3 | 2023 | 5816 | 0.710 |
Why?
|
Substance Abuse, Intravenous | 1 | 2024 | 529 | 0.670 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 2023 | 353 | 0.640 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2024 | 694 | 0.590 |
Why?
|
Symporters | 1 | 2020 | 360 | 0.580 |
Why?
|
Chest Pain | 1 | 2024 | 1090 | 0.570 |
Why?
|
Prediabetic State | 1 | 2022 | 547 | 0.540 |
Why?
|
Staphylococcal Infections | 1 | 2024 | 1406 | 0.500 |
Why?
|
Obesity | 4 | 2024 | 12870 | 0.490 |
Why?
|
Cardiovascular Diseases | 4 | 2024 | 15399 | 0.490 |
Why?
|
Myocytes, Cardiac | 2 | 2020 | 1655 | 0.460 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2023 | 1309 | 0.460 |
Why?
|
Induced Pluripotent Stem Cells | 3 | 2020 | 1842 | 0.450 |
Why?
|
Endothelium, Vascular | 2 | 2022 | 4429 | 0.440 |
Why?
|
Kidney Diseases | 1 | 2023 | 2083 | 0.400 |
Why?
|
Heart Transplantation | 2 | 2023 | 3220 | 0.400 |
Why?
|
Acute Kidney Injury | 1 | 2024 | 1926 | 0.390 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2024 | 2239 | 0.350 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2024 | 3432 | 0.340 |
Why?
|
Biphenyl Compounds | 2 | 2024 | 988 | 0.320 |
Why?
|
Hospitalization | 3 | 2024 | 10652 | 0.300 |
Why?
|
Drug Combinations | 2 | 2024 | 2020 | 0.290 |
Why?
|
Humans | 37 | 2024 | 758406 | 0.290 |
Why?
|
Angiotensin Receptor Antagonists | 2 | 2024 | 1016 | 0.280 |
Why?
|
Benzhydryl Compounds | 2 | 2024 | 900 | 0.280 |
Why?
|
Practice Guidelines as Topic | 1 | 2024 | 7378 | 0.270 |
Why?
|
Medicare | 1 | 2024 | 6741 | 0.260 |
Why?
|
Atrial Fibrillation | 1 | 2024 | 5103 | 0.250 |
Why?
|
Suppuration | 1 | 2024 | 61 | 0.240 |
Why?
|
Pericarditis, Constrictive | 1 | 2024 | 46 | 0.240 |
Why?
|
Pericardiocentesis | 1 | 2024 | 78 | 0.230 |
Why?
|
Myocardial Infarction | 2 | 2022 | 11424 | 0.230 |
Why?
|
Hypertension | 1 | 2023 | 8499 | 0.220 |
Why?
|
Naphthyridines | 1 | 2024 | 138 | 0.220 |
Why?
|
Hypoglycemic Agents | 3 | 2024 | 3069 | 0.210 |
Why?
|
Sodium-Glucose Transporter 2 | 1 | 2023 | 89 | 0.210 |
Why?
|
Cardiac Myosins | 1 | 2023 | 127 | 0.210 |
Why?
|
Diuretics | 1 | 2024 | 610 | 0.190 |
Why?
|
Fentanyl | 1 | 2024 | 433 | 0.190 |
Why?
|
Tetrazoles | 2 | 2024 | 899 | 0.180 |
Why?
|
Stress, Mechanical | 2 | 2022 | 1664 | 0.180 |
Why?
|
Conservation of Natural Resources | 1 | 2023 | 211 | 0.180 |
Why?
|
New York | 1 | 2022 | 874 | 0.170 |
Why?
|
Hepatitis B, Chronic | 1 | 2024 | 403 | 0.170 |
Why?
|
Glucosides | 1 | 2024 | 498 | 0.170 |
Why?
|
American Heart Association | 1 | 2024 | 1039 | 0.160 |
Why?
|
Aged | 11 | 2024 | 168218 | 0.150 |
Why?
|
Lung Neoplasms | 1 | 2023 | 13245 | 0.150 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2023 | 849 | 0.150 |
Why?
|
Sodium | 1 | 2023 | 1588 | 0.150 |
Why?
|
Founder Effect | 1 | 2018 | 186 | 0.150 |
Why?
|
Secondary Prevention | 1 | 2023 | 1474 | 0.140 |
Why?
|
Registries | 2 | 2024 | 8175 | 0.140 |
Why?
|
Europe | 1 | 2024 | 3420 | 0.140 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 1503 | 0.130 |
Why?
|
Nutrition Surveys | 1 | 2023 | 1716 | 0.130 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2024 | 932 | 0.130 |
Why?
|
Primary Prevention | 1 | 2023 | 1185 | 0.130 |
Why?
|
Dependovirus | 2 | 2018 | 711 | 0.130 |
Why?
|
Echocardiography | 2 | 2024 | 4962 | 0.120 |
Why?
|
Dyspnea | 1 | 2023 | 1344 | 0.120 |
Why?
|
Renal Dialysis | 1 | 2024 | 1786 | 0.120 |
Why?
|
Transduction, Genetic | 1 | 2017 | 896 | 0.120 |
Why?
|
Middle Aged | 11 | 2024 | 219568 | 0.120 |
Why?
|
Female | 13 | 2024 | 390323 | 0.120 |
Why?
|
Drug Therapy, Combination | 1 | 2024 | 6293 | 0.120 |
Why?
|
Emigrants and Immigrants | 1 | 2020 | 539 | 0.110 |
Why?
|
United States | 5 | 2024 | 72136 | 0.110 |
Why?
|
Acute Disease | 1 | 2024 | 7225 | 0.110 |
Why?
|
Tissue Donors | 1 | 2023 | 2311 | 0.110 |
Why?
|
Male | 12 | 2024 | 358747 | 0.110 |
Why?
|
Disease Management | 1 | 2024 | 2500 | 0.110 |
Why?
|
Cardiology | 1 | 2024 | 1667 | 0.100 |
Why?
|
Transfection | 1 | 2020 | 5779 | 0.100 |
Why?
|
Risk Factors | 3 | 2024 | 73809 | 0.100 |
Why?
|
Aspirin | 1 | 2023 | 3131 | 0.100 |
Why?
|
Societies, Medical | 1 | 2024 | 3891 | 0.100 |
Why?
|
Glucose | 1 | 2023 | 4336 | 0.090 |
Why?
|
Lung Transplantation | 1 | 2020 | 1305 | 0.090 |
Why?
|
Electrocardiography | 1 | 2024 | 6363 | 0.090 |
Why?
|
Health Status | 1 | 2023 | 4071 | 0.090 |
Why?
|
Prevalence | 2 | 2024 | 15651 | 0.090 |
Why?
|
Diagnosis, Differential | 1 | 2024 | 12951 | 0.080 |
Why?
|
Health Care Costs | 1 | 2021 | 3245 | 0.080 |
Why?
|
Decision Making | 1 | 2022 | 3915 | 0.080 |
Why?
|
Double-Blind Method | 3 | 2024 | 12262 | 0.070 |
Why?
|
Anti-Bacterial Agents | 1 | 2024 | 7403 | 0.060 |
Why?
|
Cell Differentiation | 2 | 2020 | 11471 | 0.060 |
Why?
|
Disease Progression | 1 | 2022 | 13468 | 0.060 |
Why?
|
Calcium | 1 | 2018 | 5721 | 0.060 |
Why?
|
Retrospective Studies | 2 | 2024 | 80168 | 0.060 |
Why?
|
Disease Models, Animal | 2 | 2020 | 18119 | 0.060 |
Why?
|
Cross-Sectional Studies | 1 | 2023 | 25956 | 0.050 |
Why?
|
Risk Assessment | 1 | 2023 | 23884 | 0.050 |
Why?
|
Aged, 80 and over | 2 | 2024 | 58683 | 0.050 |
Why?
|
Macaca mulatta | 2 | 2018 | 2316 | 0.050 |
Why?
|
Adult | 3 | 2024 | 219935 | 0.050 |
Why?
|
Cohort Studies | 1 | 2023 | 41256 | 0.050 |
Why?
|
Stage-Specific Embryonic Antigens | 1 | 2018 | 7 | 0.040 |
Why?
|
Prospective Studies | 1 | 2022 | 54137 | 0.040 |
Why?
|
HIV Infections | 1 | 2024 | 17275 | 0.040 |
Why?
|
Treatment Outcome | 4 | 2024 | 64378 | 0.040 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2018 | 223 | 0.040 |
Why?
|
Ventricular Remodeling | 1 | 2024 | 1256 | 0.030 |
Why?
|
Gene Knock-In Techniques | 1 | 2018 | 419 | 0.030 |
Why?
|
Mice | 2 | 2020 | 81101 | 0.030 |
Why?
|
Demography | 1 | 2020 | 1651 | 0.030 |
Why?
|
Fluorescence | 1 | 2018 | 749 | 0.030 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2024 | 1704 | 0.030 |
Why?
|
Genes, Reporter | 1 | 2018 | 1527 | 0.030 |
Why?
|
Animals | 3 | 2020 | 167768 | 0.030 |
Why?
|
Cardiovascular Agents | 1 | 2018 | 839 | 0.020 |
Why?
|
Patient Care Team | 1 | 2023 | 2504 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2018 | 2378 | 0.020 |
Why?
|
Blood Glucose | 1 | 2024 | 6346 | 0.020 |
Why?
|
Genetic Loci | 1 | 2018 | 2612 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2018 | 3380 | 0.020 |
Why?
|
Gene Expression | 1 | 2018 | 7583 | 0.020 |
Why?
|
Cell Line | 1 | 2018 | 15591 | 0.010 |
Why?
|